The human body contains hundreds of distinct cell types, and every one of them descends from the same fertilized egg, carrying the same genome. What distinguishes a skin cell from a liver cell, or a blood cell from a nerve cell, is not genetic information but the selective reading of that information. During development, cells become committed to specific fates, and under normal circumstances that commitment is irreversible. A blood cell cannot naturally become a nerve cell, and a skin cell cannot become a liver cell. This stability of identity is one of the defining features of multicellular life, and for most of the history of biology it was considered fixed.

That assumption changed with the advent of cellular reprogramming. By introducing a cocktail of transcription factors, researchers can force a mature cell to read a different set of genetic instructions and embark on a different developmental path. Nerve tissue can now be grown from skin cells, an achievement with obvious implications for treating neurodegenerative diseases, where specific populations of neurons are lost and replacement tissue is scarce. The Bonn group, led by Prof. Dr. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University Hospital of Bonn, has been working at this frontier for years. In earlier studies, his team showed that nerve cells produced through such reprogramming can form connections with existing neurons after transplantation into mouse brains, a critical proof of functional integration.

In the new study, the team applied a direct conversion strategy. Using transcription factor cocktails, they transformed red blood cell precursors straight into induced neural stem cells, bypassing the intermediate stage that most reprogramming protocols require. The resulting cells are restricted to the neural lineage, meaning that only brain cells can emerge from them, but they retain the proliferative capacity and developmental potential characteristic of stem cells. According to Brüstle, this direct route was the key to the study’s most striking finding, because it changed not only what the cells became but how quickly they shed the molecular marks of their age.

To measure rejuvenation, the researchers relied on molecular clocks, tools that track chemical modifications to DNA that accumulate in predictable patterns over a lifetime. These modifications, known collectively as epigenetic marks, do not alter the genetic information itself; instead, they influence how frequently particular genes are read. Because the patterns of these marks change in an orderly way as organisms age, they can be used to estimate the biological age of a cell with remarkable precision. When the Bonn team applied these clocks to their reprogrammed cells, the results were dramatic: cells derived from an 80-year-old donor emerged from the process with a molecular age of less than 20 years, a reduction of roughly six decades.

Crucially, the researchers report that this epigenetic reset is not merely cosmetic. As Brüstle notes, the rejuvenated cells actually behave like young cells, adopting the functional characteristics expected of youthful neural stem cells rather than simply displaying young-looking chemical signatures. This distinction matters, because the central question in the field of cellular rejuvenation is whether the erasure of age-related epigenetic marks corresponds to a genuine restoration of youthful function, or whether it is a superficial byproduct of reprogramming. The Bonn results support the former interpretation, at least for this conversion pathway.

What makes the study genuinely novel, however, is not the fact of rejuvenation but its tempo. Rejuvenation during reprogramming had been observed before, but only in two-step protocols, in which a blood cell is first converted into a pluripotent stem cell, a state in which virtually every career path in the body remains open, and that pluripotent cell is then directed to become a neural stem cell. In that conventional approach, rejuvenation happens very rapidly, compressed into the early phase of the conversion, and is therefore difficult to dissect experimentally. The direct conversion used in Bonn unfolded very differently. Because the blood cells were transformed into neural stem cells without passing through the pluripotent stage, the epigenetic clocks were reset gradually, and the researchers were able to track the process for more than 100 days.

This protracted timeline is what transforms the system from a curiosity into a tool. Rejuvenation that extends over weeks rather than days provides an experimental window through which the underlying mechanisms can be observed in real time. As the researchers point out, because the epigenetic clocks are slowly reset over an extended period, the model can be used to test which factors and active substances accelerate or slow down the rejuvenation process. In effect, the slow conversion turns cellular de-aging into something that can be measured, perturbed, and modulated in the laboratory, opening the door to systematic screens for compounds that influence how cells shed their age-related marks.

The implications extend well beyond basic developmental biology, and the Bonn team is explicit about where they see the greatest relevance. Age is the single most important risk factor for neurodegenerative diseases such as Alzheimer’s, and understanding how the aging process is encoded in cells, and how that encoding can be reversed, is central to any long-term strategy for prevention or treatment. A model in which human cells visibly and gradually de-age over months offers neuroscientists a way to ask precise questions about which molecular events accompany the loss of aging signatures, and whether intervening in those events could protect vulnerable cell types in the aging brain.

The research was carried out by groups from the University Hospital of Bonn, the University of Bonn, and RWTH Aachen University, with funding from the European Union’s Horizon 2020 program, the German Research Foundation, and the Federal Ministry of Research, Technology, and Space. The work, published under the title describing protracted fate acquisition and epigenetic de-aging during induced neural stem cell conversion of human blood cells, adds a new dimension to the growing field of cellular reprogramming. It suggests that the road from an aged blood cell to a youthful brain cell can be made long enough to study, and that in that length lies an opportunity: the chance to finally watch, step by step, what it means for a cell to grow young again.

Subject of Research: Direct reprogramming of human blood cells into induced neural stem cells with epigenetic age reversal

Article Title: Researchers transform old blood cells into young brain cells

Article References: Researchers transform old blood cells into young brain cells. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cellular reprogramming, epigenetic clocks, neural stem cells, aging, red blood cell precursors, induced neural stem cells, neurodegenerative disease, Alzheimer's disease, University of Bonn, Aging Cell, transcription factors, epigenetics

The work builds on a technique known as direct conversion, in which specialized cells are pushed into a new identity without passing through the pluripotent state that defines induced pluripotent stem cells, or iPSCs. When somatic cells are reprogrammed into iPSCs, their DNA methylation age — a molecular readout of biological aging — is rewound to an embryonic state. In contrast, when cells are converted directly into post-mitotic neurons, they largely retain the age of the cells they came from. The new study sits intriguingly between these two poles: induced neural stem cells, or iNSCs, are self-renewing like stem cells, yet they are generated without a pluripotent intermediate.

The research team, led by investigators at the University of Bonn, used a Sendai virus system to deliver just two transcription factors, SOX2 and cMYC, into erythroid progenitor cells derived from easily accessible blood samples. Within days of infection, the blood cells downregulated the erythroid marker CD71, and by day twelve, the emerging cells expressed the neural stem cell markers DACH1 and PAX6. Morphologically, the cultures already resembled neuroepithelial tissue within the first two weeks. On the surface, the fate switch appeared to happen quickly.

But the molecular data told a different story. Using the epigenetic clock algorithm developed by Steve Horvath and colleagues, the researchers measured DNA methylation age across the conversion time course. While the starting blood cells correlated precisely with the chronological age of their donors, the converted iNSCs at low passage carried a DNA methylation age averaging only about thirteen percent of the donor’s chronological age — and in established lines, less than five percent. Remarkably, this de-aging did not happen in a burst. Instead, it stretched across approximately fifty days, with some individual lines requiring around seven weeks to reach roughly twenty percent of their original epigenetic age.

This slow kinetics stands in sharp contrast to classic iPSC reprogramming, where the epigenetic age reset is largely complete within about twenty days. The protracted timeline suggests that the molecular machinery responsible for erasing age-related methylation signatures operates on a different schedule when pluripotency is not engaged. The researchers also compared their iNSCs with isogenic iPSC-derived neural stem cells generated from the same blood samples, providing a matched reference for cells that have undergone a complete age reset through the pluripotent route.

Perhaps the most unexpected result came from experiments designed to test whether cell division drives the de-aging process. Because both iPSC reprogramming and iNSC conversion involve proliferating cells, while direct conversion into non-dividing neurons preserves epigenetic age, the team hypothesized that mitotic activity might be the engine of rejuvenation. To test this, they slowed proliferation during conversion using either glycerol or thymidine, both of which significantly reduced accumulated population doublings. Yet the epigenetic de-aging continued essentially unabated. Even when the researchers forced the converting cells to differentiate into neurons by overexpressing NGN2 — producing cultures dominated by TUBB3-positive neurons — the DNA methylation age continued to decline at a rate indistinguishable from proliferating controls.

This finding implies that epigenetic de-aging during neural conversion is not simply a byproduct of stem cell self-renewal. It may instead be driven by the sustained presence of the conversion factors themselves, or by molecular processes that operate independently of both cell division and fate consolidation. The researchers note that SOX2 is the one factor common to their system and to a separate study in which human fibroblasts were converted into neural plate border stem cells using BRN2, KLF4, ZIC3, and SOX2 — a conversion that also produced dramatically de-aged cells. That convergence makes SOX2 a compelling candidate for future investigations into the mechanisms of somatic cell rejuvenation.

The consolidation of neural identity itself proved equally drawn out. Genome-wide analysis of DNA methylation and RNA sequencing revealed that while early neural markers appeared within days, the full transcriptional and epigenetic remodeling continued for weeks. Genes associated with neurogenesis, axon development, and neuron projection morphogenesis were still being upregulated at the late, transgene-free stage, long after the cells had adopted a stable neural stem cell morphology. Pathways related to cell migration, adhesion, and the mesenchymal-to-epithelial transition — reflecting the dramatic shift from freely circulating blood progenitors to adherent neuroepithelial cells — were regulated across nearly all stages of conversion.

Intriguingly, the transcriptomic signatures that distinguish young from old donors faded faster than the epigenetic age markers. At the starting blood cell stage, more than 1,800 genes differed in expression between cells from newborns and those from elderly donors. By day fourteen of conversion, only twenty such genes remained differentially expressed, and at low passage, just twelve. This suggests that transcriptional de-aging may be achieved more rapidly than the deeper methylation-level reset, and that the overexpressed transcription factors may directly drive the early transcriptomic changes rather than acting through epigenetic intermediaries.

The implications extend beyond basic biology. Because iNSCs generated even from centenarian donors lack classic cellular aging hallmarks — including nuclear lamina abnormalities, impaired autophagy, mitochondrial dysfunction, and senescence markers — they closely resemble their iPSC-derived counterparts while offering a faster and more direct route to patient-specific neural cells. The extended fifty-day window of active de-aging also provides researchers with an unprecedented opportunity to dissect the mechanisms of epigenetic rejuvenation in real time, potentially offering an alternative to partial or interrupted reprogramming strategies currently being explored for anti-aging therapies. As the authors conclude, their conversion system may serve as a blueprint for future studies seeking to identify the true drivers of age reversal in somatic cells — a question that has become one of the most urgent in the biology of aging.

Subject of Research: Epigenetic de-aging and fate acquisition during direct conversion of human blood cells into induced neural stem cells

Article Title: Protracted Fate Acquisition and Epigenetic De‐Aging During Induced Neural Stem Cell Conversion of Human Blood Cells

Article References: Berg, L. J., Franzen, J., Buness, A., Konang, R., Sheng, C., Peitz, M., Till, A., Wagner, W., & Brüstle, O. (2026). Protracted Fate Acquisition and Epigenetic De‐Aging During Induced Neural Stem Cell Conversion of Human Blood Cells. Aging Cell, 25(10), Article e70751. https://doi.org/10.1111/acel.70751

Image Credits: AI Generated

DOI: 10.1111/acel.70751

Keywords: induced neural stem cells, epigenetic clock, DNA methylation age, cellular reprogramming, SOX2, cMYC, direct conversion, aging, neural stem cells, iPSC, rejuvenation, transcription factors